XM无法为美国居民提供服务。

XM无法为美国居民提供服务。
B
B

Biogen

市场新闻

Reuters - 4天前

Kaiser Permanente-backed biopharma CAMP4 raises $75 mln in US IPO

UPDATE 1-Kaiser Permanente-backed biopharma CAMP4 raises $75 mln in US IPO Adds background from paragraph 3 onwards Oct 10 (Reuters) - CAMP4 Therapeutics, a biopharmaceutical firm backed by healthcare giant Kaiser Permanente raised $75 million on Thursday in its U.S. initial public offering. CAMP4 sold 6.82 million shares in the IPO for $11 each, the company said in a statement.
B
Reuters - 6天前

Sage Therapeutics scraps Alzheimer’s drug development after trial fails; shares slide

UPDATE 3-Sage Therapeutics scraps Alzheimer’s drug development after trial fails; shares slide Adds background in paragraph 2, analyst comment in paragraph 5; updates shares Oct 8 (Reuters) - Sage Therapeutics SAGE.O said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after it failed to meet the main goal of a late-stage trial, sending its shares down 10% in premarket trading.
B
S
Reuters - 1周前

U.S. Humana, Portillos, Waters Corp

U.S. RESEARCH ROUNDUP-Humana, Portillos, Waters Corp Oct 8 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Humana, Portillos and Waters on Tuesday. HIGHLIGHTS * Frontier Communications Parent Inc FYBR.O : TD Cowen cuts to hold from buy * Humana HUM.N : RBC cuts target price to $265 from $400 * Portillos Inc PTLO.O : Stephens cuts to equal-weight from overweight * Waters Corp WAT.N : Jefferies raises to buy from hold
B
C
C
C
H
C
F
G
S
W
C
C
P
Reuters - 1周前

Scholar Rock shares jump 300% after rare disease drug scores trial win

UPDATE 3-Scholar Rock shares jump 300% after rare disease drug scores trial win Adds analyst comments in paragraphs 6 and 7, similar drugs in paragraphs 5 and 8, updates shares By Christy Santhosh Oct 7 (Reuters) - Scholar Rock's SRRK.O experimental drug achieved its main target in a late-stage trial for spinal muscular atrophy, the biotech company said on Monday, sending its shares soaring more than 300% in early trading.
B
N
R
Reuters - 1周前

Three startups aim to raise $400 mln as US biotech IPOs gain traction

UPDATE 4-Three startups aim to raise $400 mln as US biotech IPOs gain traction Adds analyst comments in paragraphs 4-5 By Niket Nishant Oct 7 (Reuters) - Three healthcare startups are looking to raise up to $400 million in their U.S. initial public offerings, underscoring the sector's strong rebound in 2024 after a two-year slump. September was the busiest month for healthcare IPOs this year, Dealogic data showed.
B
S
Reuters - 2周前

Column: Biogen and its investors both want US appeals court to clarify class certification

Column: Biogen and its investors both want US appeals court to clarify class certification The opinions expressed here are those of the author, a columnist for Reuters. By Alison Frankel Oct 2 (Reuters) - In a rare – and possibly unique – turn of events, both pharmacy company Biogen BIIB.O and its shareholders have asked a federal appeals court to grant mid-case review of a trial court decision certifying investors to bring class wide fraud claims.
B
G
Reuters - 3周前

Sage Therapeutics falls after Biogen terminates tremor drug partnership

BUZZ-Sage Therapeutics falls after Biogen terminates tremor drug partnership ** Shares of drug developer Sage Therapeutics SAGE.O fall 1% to $6.95 premarket ** Company says partner Biogen BIIB.O has terminated a licensing deal for Sage's experimental drug to treat essential tremor, effective February 2025 ** Sage had discontinued development of the
B
S
Reuters - 3周前

U.S. STOCKS Copper miners, Biogen, Salesforce

BUZZ-U.S. STOCKS ON THE MOVE-Copper miners, Biogen, Salesforce Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were set for a subdued open on Tuesday, as investors scoured for clues on what the Federal Reserve's next policy move might be, while commodity stocks got a boost after China unveiled a bumper stimulus package.
A
B
C
M
N
R
S
S
V
L
R
W
U
Reuters - 3周前

U.S. STOCKS Copper miners, Biogen, Salesforce

BUZZ-U.S. STOCKS ON THE MOVE-Copper miners, Biogen, Salesforce Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures were muted in choppy trading on Tuesday, as investors scoured for clues on what the Federal Reserve's next policy move might be, while mining stocks got a boost after China unveiled a bumper stimulus package.
A
B
C
N
R
S
V
R
U
Reuters - 3周前

Biogen rises after lupus drug meets main goal of late-stage study

BUZZ-Biogen rises after lupus drug meets main goal of late-stage study ** Shares of drugmaker Biogen BIIB.O rise 2.1% to $200 premarket ** Co and partner UCB UCB.BR say their experimental lupus treatment met the main goal of a late-stage trial ** Cos say the drug, dapirolizumab pegol, when given along with other standard of care treatments, showed
B
U
Reuters - 3周前

Eli Lilly's Alzheimer's drug approved in Japan

Eli Lilly's Alzheimer's drug approved in Japan Sept 24 (Reuters) - Eli Lilly LLY.N said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing patients with another treatment option after Eisai 4523.T and Biogen's BIIB.O Leqembi received the nod in September last year. Lilly said Japan is the second major market in which the drug has received approval, after the United States where it is sold under the same brand name Kisunla.
B
Reuters - 3周前

UCB Announces Positive Results From Phase 3 Study Of Dapirolizumab Pegol

BRIEF-UCB Announces Positive Results From Phase 3 Study Of Dapirolizumab Pegol Sept 24 (Reuters) - UCB UCB.BR : UCB AND BIOGEN ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 STUDY OF DAPIROLIZUMAB PEGOL IN SYSTEMIC LUPUS ERYTHEMATOSUS ARE INITIATING SECOND PHASE 3 STUDY IN 2024 PARTICIPANTS FROM PHOENYCS GO STUDY WILL CONTINUE TO BE FOLLOWED IN A L
B
U
Reuters - 3周前

Biogen-UCB's lupus drug meets main goal of late-stage trial

CORRECTED-Biogen-UCB's lupus drug meets main goal of late-stage trial Corrects executive's name to Meyers from Myers in paragraphs 5 and 6 By Manas Mishra Sept 24 (Reuters) - Biogen BIIB.O and Belgian partner UCB UCB.BR said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in patients with the chronic disease, a surprise result after the drug failed an earlier mid-stage study.
A
B
G
U
Reuters - 3周前

Kaiser Permanente-backed biopharma CAMP4 files for US IPO

UPDATE 2-Kaiser Permanente-backed biopharma CAMP4 files for US IPO Adds financial and other details about company in paragraphs 2 and 4, industry context in paragraph 3 Sept 20 (Reuters) - CAMP4 Therapeutics, a biopharmaceutical firm backed by healthcare giant Kaiser Permanente, filed for an initial public offering in the United States on Friday. Founded in 2016, the Cambridge, Massachusetts-based company is developing therapies to treat a broad range of genetic diseases.
B
Reuters - 4周前

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds price and availability in paragraph 4 Sept 13 (Reuters) - The U.S. Food and Drug Administration on Friday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The subcutaneous or under-the-skin therapy called Ocrevus Zunovo has the potential to expand treatment options to centers unable to administer the IV version.
B
N
R
Reuters - 4周前

US FDA approves injectable version of Roche's multiple sclerosis therapy

US FDA approves injectable version of Roche's multiple sclerosis therapy Sept 13 (Reuters) - The U.S. Food and Drug Administration on Friday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The subcutaneous or under-the-skin therapy called Ocrevus Zunovo has the potential to expand treatment options to centers unable to administer the IV version.
B
N
R
Reuters - 1个月前

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds background throughout Sept 12 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The therapy is already approved as an infusion or IV therapy for multiple sclerosis, which is given twice a year, under the brand name Ocrevus.
B
N
R
Reuters - 1个月前

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds background throughout Sept 12 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The therapy is already approved as an infusion or IV therapy for multiple sclerosis, which is given twice a year, under the brand name Ocrevus.
B
N
R
Reuters - 1个月前

Biogen Board Appoints Two New Independent Directors

BRIEF-Biogen Board Appoints Two New Independent Directors Sept 12 (Reuters) - Biogen Inc BIIB.O : BIOGEN BOARD APPOINTS TWO NEW INDEPENDENT DIRECTORS BIOGEN INC - APPOINTS LLOYD MINOR AND MENELAS PANGALOS AS INDEPENDENT DIRECTORS Source text for Eikon: ID:nGNX3jZhPK Further company coverage: BIIB.O
B
Reuters - 1个月前

Bio-Thera Solutions And Biogen Publish Phase 3 Clinical Trial Data For TOFIDENCE

BRIEF-Bio-Thera Solutions And Biogen Publish Phase 3 Clinical Trial Data For TOFIDENCE Sept 11 (Reuters) - Bio-Thera Solutions Ltd 688177.SS : BIO-THERA SOLUTIONS AND BIOGEN PUBLISH PHASE 3 CLINICAL TRIAL DATA FOR TOFIDENCE™ BIO-THERA SOLUTIONS: COMPARABLE CLINICAL EFFICACY, SAFETY IN TREATMENT PERIOD 2 IS MAINTAINED AFTER SWITCH FROM REFERENCE T
B

商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。

风险提示： 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明。